Syngene International Ltd logo

Syngene International Ltd

SYNGENE NSE

Key Fundamentals

SmallcapHealthcare TechnologyHealthcare
Market Cap
₹16,389 Cr
Volatility
Moderate
P/E Ratio
73.61
EBITDA
₹989 Cr
Return on Equity
6.54%
Debt to Equity
0.09
Book Value
₹119.9
EPS
₹11.85
52W High
₹684.6
52W Low
₹375.25

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Syngene International Ltd insights

45 extracted metrics + investor summaries across FY11–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

4
  • Stock is trading at 3.36 times its book value
  • The company has delivered a poor sales growth of 11.4% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Dividend payout has been low at 12.0% of profits over last 3 years

Growth Rate

Revenue Growth
2.56% ↗
Net Income Growth
-36.17% ↗
Cash Flow Change
-21.62% ↘
ROE
-37.71% ↗
ROCE
-36.74% ↗
EBITDA Margin (Avg.)
-13.38% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 4d ago
AI opinion · based on fundamentals
Risk high

Syngene International trades at a PE of 74.8x with a market cap of Rs 16,544 Cr, while facing a TTM sales decline of -3% and a sharp -42% TTM profit decline. The company is nearly debt-free but has seen its stock price fall 38% over the past year with ROE declining to 8% in the last year from a 5-year average of 11%.

Bull Case 7
  • Company is almost debt-free, having actively reduced debt, which strengthens the balance sheet and reduces financial risk
  • 10-year stock CAGR of 7% demonstrates long-term wealth creation track record despite recent corrections
  • 5-year compounded sales growth of 11% shows the company has been able to grow its top line over a medium-term horizon
  • 5-year average ROE of 11% indicates reasonable capital efficiency for a CDMO/research services business
  • Dividend yield of 0.31% with low 12% payout ratio means significant retained earnings are available for reinvestment and future growth
  • Price-to-book of 3.41x is relatively moderate for a healthcare/CDMO platform company with asset-light potential
  • Market cap of Rs 16,544 Cr positions it as a mid-to-large cap with institutional investor accessibility and liquidity
Bear Case 8
  • TTM compounded profit has declined -42%, indicating severe earnings compression in the most recent period
  • Stock has fallen -38% in the past 1 year, reflecting significant market de-rating and loss of investor confidence
  • PE ratio of 74.8x is extremely elevated, especially given negative recent profit growth, suggesting expensive valuation relative to current earnings
  • TTM sales growth is -3%, showing top-line contraction and potential demand weakness in the current environment
  • 3-year compounded profit growth of -8% indicates a multi-year earnings deterioration trend, not just a one-off
  • ROE has declined from 11% (5-year average) to 8% in the last year, signaling deteriorating return on shareholder capital
  • 3-year stock CAGR of -20% shows sustained value destruction for medium-term investors
  • 5-year compounded profit growth is 0%, meaning no incremental earnings have been generated over half a decade despite sales growing 11%

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 20h ago
Headwinds 2
  • Q1 net loss on FX hit Jul 29

    Syngene posted a standalone net loss of ₹21 million in Q1FY27, driven by ₹480 million forex loss and termination benefits. Revenue fell 17% YoY to ₹6,630 million.

  • FY27 revenue decline guided Jul 31

    Management revised FY27 guidance to single-digit revenue decline in rupee terms with EBITDA margins in mid-20s, citing absence of Zoetis offtake and Research Services client attrition concentrated in H1 FY27.

Positives 2
  • ₹1.25 dividend declared at AGM Jul 29

    Syngene declared a final dividend of ₹1.25 per share for FY26 at its 33rd AGM on July 29, 2026, alongside appointment of new statutory auditors and board reappointments.

  • CDMO business strategic doubling down Jul 30

    Syngene announced plans to intensify focus on its CDMO business in FY27, positioning it as a central pillar of operations with margin recovery expected in H2 FY27 and return to profitable growth from FY28.

Neutral 3
  • Q1 FY27 earnings call held Jul 30

    Syngene hosted its Q1 FY27 earnings conference call on July 30, 2026 at 9:00 AM IST as per SEBI Listing Regulations.

  • Independent Director Parmar resigns Jul 29

    Kush Parmar resigned as Independent Director effective July 29, 2026, citing increasing commitments in the USA and residence outside India.

  • Bayview facility deferred to post-FY27 Jul 31

    Bayview facility will not be capitalised in FY27, keeping associated P&L expenses minimal for the current fiscal year.

TL;DR: Syngene is navigating a tough H1 FY27 with a 17% YoY revenue drop, forex headwinds, and client attrition from Zoetis and Research Services. The CDMO pivot and cost optimisation offer a credible recovery path for H2 FY27 and FY28. Dividend continuity signals board confidence despite near-term earnings pressure. The trend is deteriorating in the short term but management is guiding toward stabilisation by year-end.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
808
910
854
917
790
891
944
1,018
875
911
917
1,037
736
Expenses
596
656
622
600
620
646
660
674
668
711
708
733
645
Operating Profit
212
254
232
317
170
245
284
344
206
200
209
303
90.8
OPM %
26.22%
27.92%
27.12%
34.56%
21.5%
27.47%
30.05%
33.75%
23.6%
21.91%
22.81%
29.27%
12.34%
Other Income
23.6
14.2
25.6
16.1
50.1
16.5
18.3
18.9
17.7
15.4
-55.2
16.2
11.8
Interest
10.5
13
10.8
12.9
11.7
13.1
12.4
15.9
11.6
13.2
11.9
12.1
9.6
Depreciation
102
105
108
111
107
111
109
106
111
117
114
112
112
PBT
123
151
138
209
101
137
181
241
101
85.2
28.4
196
-19.2
Tax %
24%
22.69%
19.32%
9.76%
25.27%
22.72%
27.49%
23.78%
14.41%
21.24%
47.18%
24.54%
-53.12%
Net Profit
93.4
117
112
189
75.7
106
131
183
86.7
67.1
15
148
-9
EPS in Rs
2.32
2.9
2.77
4.69
1.88
2.64
3.26
4.55
2.15
1.67
0.37
3.67
-0.22
Figures in ₹ Crores

Profit & Loss

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,423
1,826
2,012
2,184
2,604
3,193
3,489
3,642
3,739
3,600
Expenses
949
1,289
1,394
1,507
1,861
2,251
2,472
2,598
2,817
2,797
Operating Profit
474
537
618
678
743
942
1,017
1,045
921
803
OPM %
33%
29%
31%
31%
29%
30%
29%
29%
25%
22%
Other Income
53
75
153
94
75
63
77
101
-9
-12
Interest
23
32
35
28
24
45
47
53
49
47
Depreciation
131
164
219
274
310
366
426
433
453
454
PBT
372
415
517
469
484
594
621
660
411
290
Tax %
18%
20%
20%
14%
18%
22%
18%
25%
23%
—
Net Profit
305
332
412
405
396
464
510
496
317
221
EPS in Rs
7.64
8.29
10.3
10.12
9.88
11.57
12.69
12.33
7.86
5.49
Div. Payout %
7%
3%
0%
0%
10%
11%
10%
10%
16%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
200
200
400
400
401
401
402
402
403
Reserves
1,520
1,768
1,776
2,421
2,897
3,217
3,856
4,324
4,436
Borrowings
787
813
773
893
1,022
815
555
578
458
Other Liabilities
681
922
1,214
1,169
1,245
1,398
1,339
1,491
1,757
Total Liabilities
3,189
3,704
4,163
4,883
5,564
5,831
6,152
6,796
7,055
Fixed Assets
1,030
1,377
2,020
2,201
2,393
2,667
2,850
2,802
3,000
CWIP
155
274
234
237
346
177
838
1,266
1,046
Investments
158
716
776
702
1,034
918
548
647
741
Other Assets
1,846
1,337
1,133
1,743
1,790
2,069
1,916
2,081
2,268
Total Assets
3,189
3,704
4,163
4,883
5,564
5,831
6,152
6,796
7,055
Figures in ₹ Crores

Cash Flow

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
446
630
677
701
581
824
1,042
1,168
915
Investing
-349
-646
-424
-629
-611
-653
-494
-744
-839
Financing
-79
-72
-226
58
-31
-342
-551
-142
-215
Net Cash Flow
18
-88
28
130
-62
-172
-4
281
-138
Free Cash Flow
82
47
34
255
105
305
553
398
547
CFO/OP
111
135
127
116
92
102
115
123
107
Figures in ₹ Crores

Ratios

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
68
72
79
71
61
46
53
50
Inventory Days
82
30
18
41
87
141
94
60
56
Days Payable
195
154
156
167
113
109
100
136
138
Cash Conversion Cycle
-44
-56
-66
-47
45
92
40
-23
-32
Working Capital Days
-48
-103
-172
-66
-43
-14
-27
-51
-68
ROCE %
—
17%
17%
14%
13%
15%
15%
13%
10%

Shareholding Pattern

As of Jun 2026
Promoters 52.59%
DIIs 28.02%
FIIs 11.82%
Public 6.14%
Others 1.44%
Total 100.01%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
70.58%
70.43%
70.42%
70.41%
70.41%
70.29%
64.86%
64.86%
54.88%
54.80%
54.79%
54.79%
54.79%
54.72%
54.72%
52.74%
52.74%
52.68%
52.68%
52.68%
52.68%
52.59%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.02%
0.02%
0.00%
0.00%
0.00%
20.92%
20.63%
20.72%
20.64%
19.47%
16.50%
16.31%
14.96%
13.90%
11.82%
DIIs
4.02%
3.81%
4.03%
3.64%
3.26%
2.79%
4.96%
7.04%
10.73%
11.20%
9.94%
13.08%
15.80%
16.80%
17.48%
19.53%
21.50%
24.05%
24.62%
25.84%
26.44%
28.02%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
8.05%
8.29%
8.46%
9.20%
9.22%
9.02%
8.81%
8.57%
8.39%
8.10%
7.53%
7.24%
6.45%
6.08%
5.45%
5.59%
5.08%
5.59%
5.28%
5.37%
5.51%
6.14%
Others
17.35%
17.46%
17.09%
16.76%
17.11%
17.90%
21.36%
19.52%
25.98%
25.90%
27.73%
24.89%
2.03%
1.77%
1.62%
1.50%
1.21%
1.18%
1.10%
1.15%
1.46%
1.44%
No. of Shareholders
1,15,632
1,26,395
1,36,749
1,37,892
1,33,610
1,28,278
1,34,334
1,27,964
1,24,014
1,25,455
1,25,992
1,21,880
1,15,850
1,20,018
1,07,338
1,28,806
1,25,090
1,42,310
1,36,061
1,31,750
1,35,605
1,42,277

Documents

Frequently Asked Questions about Syngene International Ltd

What does Syngene International Ltd do?
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufactu...
Where is Syngene International Ltd (SYNGENE) listed?
Syngene International Ltd is listed on the Indian stock exchanges. It is listed on NSE: SYNGENE and BSE: 539268. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Syngene International Ltd belong to?
Syngene International Ltd operates in the Healthcare sector within the Healthcare Services industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Syngene International Ltd?
Syngene International Ltd has a market capitalisation of approximately ₹16388.97 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Syngene International Ltd?
The Price-to-Earnings (PE) ratio of Syngene International Ltd is 73.61. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Syngene International Ltd?
Over the past 52 weeks, Syngene International Ltd has traded between a low of ₹375.25 and a high of ₹684.6. This range helps investors understand the stock's price volatility and recent trading levels.
Does Syngene International Ltd pay dividends?
Yes, Syngene International Ltd has a dividend yield of 0.31%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Syngene International Ltd?
Syngene International Ltd has a Return on Equity (ROE) of 6.54%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Syngene International Ltd on Tapetide?
On Tapetide, you can view Syngene International Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Website syngeneintl.com
CEO Mr. Peter James Jonathan Bains
Employees 6,533
Listed 2015-08-11
Face Value ₹ 10
Issued Size 40,29,39,420

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List